Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Mimotopes enters licensing deal with Baker Institute
November 2007
SHARING OPTIONS:

MELBOURNE, AustraliaŚMimotopes Pty. Ltd. has entered into a licensing agreement with the Baker Heart Research Institute (BHRI) for jointly developed drug candidates targeting pulmonary arterial hypertension. As part of the licensing agreement, Mimotopes has assigned the intellectual property for a library of compounds to BHRI in return for a future milestone and/or licensing fees received by BHRI. Mimotopes will also contribute its medicinal chemistry expertise on a fee-for-service basis to assist in the clinical development of these compounds.
Dr. Bev Thomas, BHRI commercialization manager, says BHRI's extensive experience in technology transfer would boost the collaboration between the groups and enhance the potential for practical application of treatments developed as a result of the partnership. "While the initial target therapeutic application is pulmonary arterial hypertension, this agreement could see the application of new therapies to a wide range of cardiovascular diseases," she notes.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.